OMV-C9I12

OMV-C9I12 is an engineered gene therapy platform based on bacterial outer membrane vesicles (OMVs) derived from E. coli BL21, designed to deliver genes encoding CXCL9 and IL12 into tumor cells. This approach reprograms tumor cells to secrete the chemokine CXCL9 and the cytokine IL-12, resulting in enhanced T-cell chemotaxis, activation, and antitumor immune responses. OMV-C9I12 has demonstrated the ability to potentiate T cell–mediated immunotherapy, suppress tumor growth, and extend survival in humanized mouse models of bladder and breast cancer. The technology synergizes with immune checkpoint inhibitors such as anti-PD-1 and anti-PD-L1 therapies, marking it as a novel gene therapy strategy for overcoming resistance to immunotherapy and enhancing efficacy in cancer treatment[1][4][10].